Clinical Psychiatry News - FDA warns manufacturers about ADHD drug claims
January 12th, 2009 The Food and Drug Administration has warned five manufacturers of drugs for attention-deficit/hyperactivity disorder against using what it terms “false or misleading” promotional materials that overstate the drugs’ efficacy and downplay risks.
The warnings, contained in letters sent in late September to the makers of Adder-all XR, …
Pediatric News - Strattera
January 9th, 2009 Strattera (atomoxetine HCl, Eli Lilly & Co.)
The Food and Drug Administration approved Strattera for attention-deficit/hyperactivity disorder maintenance therapy in children and adolescents aged 6 years and older. This is the first FDA-approved agent for ma…
Pediatric News - Strattera now available
January 7th, 2009Strattera (atomoxetine), the first non-stimulant approved for the treatment of attention-deficit hyperactivity disorder is now available by prescription in pharmacies nationwide. Strattera also is approved for treating attention-deficit hyperactivity disorder in adults. For more informatio…
Chain Drug Review - FDA grants approval to Eli Lilly’s Strattera
January 5th, 2009INDIANAPOLIS — Eli Lilly and Co. has received Food and Drug Administration clearance for Strattera (atomoxetine HCl) for maintenance treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. Strattera, a selective nor…
Drug Cost Management Report - Eli Lilly’s new drug for attention deficit hyperactivity disorder , Strattera, may have trouble getting reimbursement from HMO formularies - ADHD - Eli Lilly…
December 29th, 2008* Eli Lilly’s new drug for attention deficit hyperactivity disorder (ADHD), Strattera, may have trouble getting reimbursement from HMO formularies, according to a study by Decision Resources. The drug is a latecomer to this therapeutic category, which includes some generics, and relationships between HMOs and manufacturers are fairly well-cemented.
Relat…
AScribe Health News Service - Study Shows Treatment With ADHD Medication May Be As Effective in African American Children With ADHD As in Caucasian Children With ADHD; Data Suggests Greater…
December 23rd, 2008 Byline: Fleishman Hillard
SAN DIEGO, Calif., Aug. 3 (AScribe Newswire) — African American and Caucasian children with Attention Deficit/Hyperactivity Disorder (ADHD) who took Concerta (methylphenidate HCl) CII demonstrated greater improvement in symptoms such as hyperactivity, impulsivity, and attention than they did with Strattera (atomoxetine), according to a subgroup analysis of…
Bad and Good News
December 18th, 2008Only 15% of adults with ADHD have been diagnosed. This is the dismaying statistic that I have been pondering this past month. That means that 85% of the adults with ADHD don’t know it and they continue to live chaotic and difficult lives. The limited number of adults who know the…
ADHD Medication Roundup
December 14th, 2008Once you have been diagnosed with ADHD by a mental health professional, your doctor is likely to recommend treatment with medication. Medication can significantly reduce your ADHD-related symptoms and make your life much easier. The first choice for medication treatments are stimulant…
The Latest ADD/ADHD Drug Treatments: What Is Really New and What Is Not New
December 12th, 2008The latest drugs for ADD/ADHD are, most of them, forms of amphetamines or methylphenidate - which have been used to treat hyperactivity since the 1960s. Here’s a list of the ADD/ADHD medications approved after 2000, and a description of how they are better than the older drugs: 1. Methylphenidate drugs Focalin XR, Ritalin LA, Concerta, and Metadate CD are all long-acting, extended release versions of methylphenidate. T…
PR Newswire UK Disclose - LILLY (ELI) & COMPANY - Lilly Announces Important Strattera Label Update.
December 7th, 2008 Most Popular
3 Questions No Job Seeker Ever Wants To Be Asked?
10 Jobs That Pay $30 An Hour
13 Job Interview Mistakes To Avoid
5 Regular Mistakes In Public Speaking
Interpersonal Communication: Styles Of Conflict
re>
Date: September 29, 2005
For Release: Immediately
Refer to: Jennifer Bunsel…

